Featured Courses

The Management of Common AD-Related Comorbidities

AMA PRA Category 1 Credit(s)^TM

In this case-based activity, two physician experts in the management of AD are joined by a longtime patient with AD to discuss some of the most significant challenges patients with AD and comorbidities face on a day-to-day basis.

Emerging and Investigational Therapies for Moderate-to-Severe AD

AMA PRA Category 1 Credit(s)^TM

This case-based activity features insight from two expert physicians as well as a caregiver of a longtime AD patient to provide 360-degree insight on current and potential future strategies for the management of moderate-to-severe AD.

Stepwise Therapy in the Management of Atopic Dermatitis

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

Part of the National Eczema Association’s Coalition United for Better Eczema Care (CUBE-C) educational series, this activity will share the quality of life perspectives of a patient with atopic dermatitis (AD) and then review the use of stepwise therapy in the management of AD.

Impact of Atopic Dermatitis on Patient Quality of Life and Psychosocial Development

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

Part of the National Eczema Association’s Coalition United for Better Eczema Care (CUBE-C) educational series, this activity will discuss psychosocial aspects of AD to better inform diagnosis, treatment and management as well as the role of the patient in the shared decision making process.

What Does the Future Hold in the Treatment of Atopic Dermatitis?

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

Part of the National Eczema Association’s Coalition United for Better Eczema Care (CUBE-C) educational series, this activity will the impact AD has on a patient’s QOL, as well as current and emerging agents for the treatment of AD.

Best Practices in Atopic Dermatitis for Pediatric Clinicans | myCME

AMA PRA Category 1 Credit(s)^TM

Although PCPs and pediatricians are seeing an increase in AD cases, recent evidence shows these clinicians are lacking in their ability to accurately diagnose and assess disease severity. Education to ensure clinicians are prepared to effectively diagnose and assess disease severity is therefore necessary.

The Patient Voice: Defining Health Care Disparities in Atopic Dermatitis Care

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), ABIM MOC Points, CE for Pharmacists

This activity will feature patient voices in addition to expert faculty discussing the implementation of best practices for diagnosing, evaluating, and treating AD among patients of color, the latest evidence on health care disparities in patients with AD and the impact of COVID-19 on the care of patients of color with AD.

More Targets, More Targeted Therapies: Evolving Concepts and Therapies for Atopic Dermatitis

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

This program will address the role of new and emerging targeted therapy agents within the context of mild to severe AD.

Unmet Needs of Patients with Atopic Dermatitis | myCME

AMA PRA Category 1 Credit(s)^TM

0.75 CME: Reviews the burden and unmet needs of AD, 2014 guidelines, and most recent data supporting approved and emerging therapies. Exp 10/29/22

The Burden of Prurigo Nodularis: New Targeted Treatments | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

0.50 CME CE: Prurigo nodularis results in high personal and socioeconomic costs. Targeted therapies may alleviate some of these. Learn more! Exp. 3/30/2023

Targeting Disease Mechanisms in Prurigo Nodularis | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

0.50 CME CE: Current PN therapies often do not meet treatment goals. Emerging, targeted treatment strategies are on the horizon for PN patients. Exp 3/30/23

Novel Mechanisms in Prurigo Nodularis | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

0.50 CME CE There are limited treatment options for PN. This interactive activity provides an overview of how emerging therapies target its underlying pathophysiology. Exp 3/31/23